UNRAVELING THE MOLECULAR LANDSCAPE OF BREAST CANCER: PROTEOMIC PERSPECTIVES AND CLINICAL IMPLICATIONS

Sunil Saini*, Kamal Singh Rathore and Khatri Upasana

Breast cancer, a heterogeneous disease with diverse molecular subtypes, poses significant challenges in diagnosis and treatment. In this comprehensive review, we delve into the intricate landscape of breast cancer classification and biomarkers, encompassing various types and their distinct characteristics. From hormone receptor-positive BRCA to triple-negative breast cancer (TNBC) and invasive lobular carcinoma, each subtype presents unique molecular profiles and clinical implications. Through advanced proteomic techniques such as immunohistochemistry (IHC) and reverse phase protein arrays (RPPA), researchers have identified key protein biomarkers associated with prognosis and treatment response. Furthermore, the emergence of innovative tools like the CanAssist-Breast (CAB) algorithm and the integration of multi-omics data offer promising avenues for personalized treatment strategies. Looking ahead, precision medicine approaches driven by collaborative efforts between researchers, clinicians, and industry partners hold the potential to transform the landscape of breast cancer care, ultimately improving patient outcomes and quality of life.